Two cases of catastrophic antiphospholipid syndrome

Abstract

Catastrophic antiphospholipid syndrome (CAPS) is a rare complication of antiphospholipid syndrome. lt is a disseminated severe vascular pathology which presents with multi-organic dysfunction that progresses rapidly. Prognosis ends up being fatal in half of the cases. It may appear during pregnancy, surgery, infection, or after suspension of anticoagulation therapy. We studied two female patients with CAPS who survived after treatment with anticoagulation therapy and intravenous corticosteroids. The evolution of our two patients, after 17 months of follow-up under oral anticoagulant treatment was favourable and they are currently asymptomatic. In these patients the early diagnosis and treatment were essential to enhance their possibilities of survival.

Keywords

anticoagulation catastrophic antiphospholipid syndrome corticosteroids survival

Get full access to this article

View all access options for this article.

References

Wilson WA , Gharavi AE , Koike T et al. International consensus statement on preliminary classification criteria for definite anti-phospholipid syndrome: report of an internacional workshop . Arthritis Rheum 1999; 42: 1309-1311 .

Gómez-Puerta J , Gil V , Cervera R. “Catastrophic” antiphospholipid syndrome . Mayo Clinic Proceedings 2003; 78: 519-519 .

Levine JS , Branch DW , Rauch J. The antiphospholipid syndrome . N Engl J Med 2002; 346: 752-763 .

Schaar CG , Ronday KH , Boets EP , van der Lubbe PA , Breedveld FC. Catastrophic manifestations of the antiphospholipid syndrome . J Rheumatol 1999; 26: 2261-2264 .

Asherson RA , Piette JC. The catastrophic antiphospholipid syndrome 1996. Acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients . Lupus 1996; 5: 414-417 .

Asherson RA , Espinosa G , Cervera F , Font J , Reverter JC. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment . J Clin Rheumatol 2002; 8: 157-165 .

Asherson RA , Cervera R , Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients . Medicine 1998; 77: 195-207 .

Asherson RA , Cervera R , de Groot PE et al. Catastrophic antiphospholipid síndrome: international consensus statement on classification criteria and treatment guidelines . Lupus 2003; 12: 530-534 .

Khamastha MA , Cuadrado MJ , Mugic F et al. The management of thrombosis in the antiphospholipid antibody syndrome . N Engl J Med 1995; 332: 993-997 .

10.

Khamastha MA. The management of thrombosis and pregnancy loss in the antiphospholipid syndrome . Lupus 1998; 7: 162-165 .

11.

Schulman S , Svenungsson E , Granqvist S. Duration of Anticoagulation Study Group . Anticardiolipin antibodies predict early recurrence of thromboembolism and the death among patients with venous thromboembolism following anticoagulant therapy . Am J Med 1998; 104: 332-338 .

12.

Firshman P. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant Interleukin 3 . J Clin lnvest 1993; 91: 1834-1837 .

13.

Blank M , George J , Fishman P. Ciprofioxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of Interleukin 3 and granulocyte macrophage colony stimulating factor expression . Arthritis Rheum 1998; 41: 224-222 .

14.

Blank M , Krouse Y. Bromocriptin immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T supressors cells . Cell lmmunol 1995; 162: 144-122 .

15.

Erkan D , Yazici Y , Sobel R , Lockshin MD. Primary antiphospholipid syndrome. Functional outcome after 10 years . Rheumatol 2000; 27: 2817-2821 .

16.

Ekan D , Asherson RA , Espinosa G et al. Long term outcome of catastrophic antiphospholipid syndrome survivors . Ann Rheum Dis 2003; 62: 530-533 .